125 related articles for article (PubMed ID: 37898375)
1. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
2. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
3. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
[TBL] [Abstract][Full Text] [Related]
4. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation.
Ling S; Shan Q; Zhan Q; Ye Q; Liu P; Xu S; He X; Ma J; Xiang J; Jiang G; Wen X; Feng Z; Wu Y; Feng T; Xu L; Chen K; Zhang X; Wei R; Zhang C; Cen B; Xie H; Song P; Liu J; Zheng S; Xu X
Gut; 2020 Jul; 69(7):1322-1334. PubMed ID: 31776228
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
Wen X; Ling S; Wu W; Shan Q; Liu P; Wang C; Wei X; Ding W; Teng X; Xu X
Dig Dis Sci; 2020 Apr; 65(4):1064-1073. PubMed ID: 31587155
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance.
Chang YS; Su CW; Chen SC; Chen YY; Liang YJ; Wu JC
Cells; 2022 Feb; 11(4):. PubMed ID: 35203285
[TBL] [Abstract][Full Text] [Related]
7. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.
Ling S; Li J; Shan Q; Dai H; Lu D; Wen X; Song P; Xie H; Zhou L; Liu J; Xu X; Zheng S
Mol Oncol; 2017 Jun; 11(6):682-695. PubMed ID: 28417539
[TBL] [Abstract][Full Text] [Related]
8. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
Zhang J; Luo N; Tian Y; Li J; Yang X; Yin H; Xiao C; Sheng J; Li Y; Tang B; Li R
Oncotarget; 2017 Apr; 8(15):24728-24740. PubMed ID: 28445968
[TBL] [Abstract][Full Text] [Related]
9. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
10. METTL3-m
Wang L; Yang Q; Zhou Q; Fang F; Lei K; Liu Z; Zheng G; Zhu L; Huo J; Li X; Peng S; Kuang M; Lin S; Huang M; Xu L
Cancer Lett; 2023 Apr; 559():216122. PubMed ID: 36898427
[TBL] [Abstract][Full Text] [Related]
11. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
12. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
13. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang M; Long J; Yao Z; Zhao Y; Zhao Y; Liao J; Lei K; Xiao H; Dai Z; Peng S; Lin S; Xu L; Kuang M
Cancer Res; 2023 Jan; 83(1):89-102. PubMed ID: 36102722
[TBL] [Abstract][Full Text] [Related]
14. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
15. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
16. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
19. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
20. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
